Recommendations on reintroduction of agalsidase beta for patients with Fabry disease in Europe, following a period or shortage

Recommendations on reintroduction of agalsidase beta for patients with Fabry disease in Europe, following a period or shortage

Year of publication

2013

Authors

Linthorst GE, Burlina AP, Cecchi F, Cox TM, Fletcher JM, Feldt-Rasmussen U, Giugliani R, Hollak CE, Houge G, Hughes D, Kantola I, Lachmann R, Lopez M, Ortiz A, Parini R, Rivera A, Rolfs A, Ramaswami U, Svarstad E, Tondel C, Tylki-Szymanska A, Vujkovac B, Waldek S, West M, Weidemann F, Mehta A
Show more

Organizations and authors

University of Turku

Kantola Ilkka

Publication type

Publication format

Article

Parent publication type

Journal

Article type

Original article

Audience

Scientific

Peer-reviewed

Peer-Reviewed

MINEDU's publication type classification code

A1 Journal article (refereed), original research

Publication channel information

Volume

8

Pages

51-56

​Publication forum

78388

​Publication forum level

1

Open access

Open access in the publisher’s service

No

Self-archived

Unknown

Other information

Fields of science

Others; General medicine, internal medicine and other clinical medicine

Internationality of the publisher

Domestic

International co-publication

Yes

Co-publication with a company

Unknown

DOI

10.1007/8904_2012_160

The publication is included in the Ministry of Education and Culture’s Publication data collection

Yes

Recommendations on reintroduction of agalsidase beta for patients with Fabry disease in Europe, following a period or shortage - Research.fi